Trial reportJournal of perinatology : official journal of the California Perinatal Association2016
Clinical trial of tin mesoporphyrin to prevent neonatal hyperbilirubinemia.
Trial report in Journal of perinatology : official journal of the California Perinatal Association, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 38 citations in OpenAlex.
- Stannsoporfin with phototherapy to treat hyperbilirubinemia in newborn hemolytic disease.Journal of perinatology : official journal of the California Perinatal Association · 2022Trial
- Citrate-functionalized manganese oxide nanoparticles in neonates ≥35 weeks gestation at risk of acute bilirubin encephalopathy: a phase 1 observational trial.Pediatric research · 2026Article
- Inhibitory Potency of a Plant-Based Zinc Protoporphyrin on Heme Oxygenase Activity.Neonatology · 2026Article
- Neonatal hyperbilirubinemia: past lessons, current practices, and future directions.European journal of pediatrics · 2025Review
- Heme Oxygenase-1 and Prostate Cancer: Function, Regulation, and Implication in Cancer Therapy.International journal of molecular sciences · 2024Review
- Is it time for a precision health approach to the management of newborn hyperbilirubinemia?Journal of perinatology : official journal of the California Perinatal Association · 2024Review
- Chemoprevention of bilirubin encephalopathy with a nanoceutical agent.Pediatric research · 2023Article
- Efficacy and Safety Concerns with Sn-Mesoporphyrin as an Adjunct Therapy in Neonatal Hyperbilirubinemia: A Literature Review.International journal of pediatrics · 2022Review
- Clinical Significance of Heme Oxygenase 1 in Tumor Progression.Antioxidants (Basel, Switzerland) · 2021Review
- Exchange transfusion for hemolytic hyperbilirubinemia: could some be averted by emergent administration of an inhibitor of bilirubin production?Journal of perinatology : official journal of the California Perinatal Association · 2021Article
- Immune Modulation by Inhibitors of the HO System.International journal of molecular sciences · 2020Review
- Care of Infants Born to Women with Diabetes.Current diabetes reports · 2020Review
- Heme Oxygenase 1-Targeted Hybrid Nanoparticle for Chemo- and Immuno-Combination Therapy in Acute Myelogenous Leukemia.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2020Article
- Two Faces of Heme Catabolic Pathway in Newborns: A Potential Role of Bilirubin and Carbon Monoxide in Neonatal Inflammatory Diseases.Oxidative medicine and cellular longevity · 2020Review
- Experimental models assessing bilirubin neurotoxicity.Pediatric research · 2020Review
- Prevalence and burden of illness of treated hemolytic neonatal hyperbilirubinemia in a privately insured population in the United States.BMC pediatrics · 2019Article
- Inhibition of Heme Oxygenase-1 Activity Enhances Wilms Tumor-1-Specific T-Cell Responses in Cancer Immunotherapy.International journal of molecular sciences · 2019Article
- Umbilical cord blood bilirubins, gestational age, and maternal race predict neonatal hyperbilirubinemia.PloS one · 2018Article
- Heme oxygenase-1 promoter polymorphisms: do they modulate neonatal hyperbilirubinemia?Journal of perinatology : official journal of the California Perinatal Association · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 6 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo assess the efficacy of the heme oxygenase inhibitor, tin mesoporphyrin (SnMP), to reduce total bilirubin (TB) levels. STUDY
designMasked, SnMP (4.5 mg kg(-1)), placebo-controlled, multicenter trial of single intramuscular injection to newborns ⩾35 weeks gestational age whose predischarge screening transcutaneous bilirubin (TcB) was >75th percentile.
resultsTwo hundred and thirteen newborns (median age 30 h) were randomized to treatment with SnMP (n=87) or 'sham' (n=89). We found that the duration of phototherapy was halved. Within 12 h of SnMP administration, the natural TB trajectory was reversed. At age 3 to 5 days, TB in the SnMP-treated group was +8% but sixfold lower than the 47% increase in the sham-treated group (P<0.001). At age 7 to 10 days, mean TB declined 18% (P<0.001) compared with a 7.1% increase among controls. No short-term adverse events from SnMP treatment were noted other than photoreactivity due to inadvertent exposure to white light phototherapy.
conclusionEarly, predischarge SnMP administration decreased the duration of phototherapy, reversed TB trajectory and reduced the severity of subsequent hyperbilirubinemia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.